MedPage Today 
(6/3, Susman) reported that according to research presented at the
American Society of Clinical Oncology meeting, "Researchers said...they
were stunned by the clear preference for treatment with the targeted
agent pazopanib (Votrient) over sunitinib (Sutent) for treatment of
metastatic renal cell carcinoma. For the primary endpoint in the study –
patient preference, 70% of patients in the double-blind, crossover
study, opted for treatment with pazopanib, compared with 22% of the
patients preferring treatment with sunitinib
(P<0.001)."
(6/3, Susman) reported that according to research presented at the
American Society of Clinical Oncology meeting, "Researchers said...they
were stunned by the clear preference for treatment with the targeted
agent pazopanib (Votrient) over sunitinib (Sutent) for treatment of
metastatic renal cell carcinoma. For the primary endpoint in the study –
patient preference, 70% of patients in the double-blind, crossover
study, opted for treatment with pazopanib, compared with 22% of the
patients preferring treatment with sunitinib
(P<0.001)."
HealthDay
(6/3, Dallas) reported that approximately "60 percent of physicians
preferred Votrient, while 21 percent opted for Sutent and 21 percent had
no preference."
(6/3, Dallas) reported that approximately "60 percent of physicians
preferred Votrient, while 21 percent opted for Sutent and 21 percent had
no preference."
No comments:
Post a Comment